Immutep Limited, a biotechnology company, is dedicated to the research and development of pharmaceutical candidates. The company is headquartered in Sydney, Australia.
| Revenue (TTM) | $7.92M |
| Gross Profit (TTM) | $-74.78M |
| EBITDA | $-82.39M |
| Operating Margin | -764.00% |
| Return on Equity | -61.90% |
| Return on Assets | -32.10% |
| Revenue/Share (TTM) | $0.05 |
| Book Value | $0.05 |
| Price-to-Book | 0.79 |
| Price-to-Sales (TTM) | 6.61 |
| EV/Revenue | 115.06 |
| EV/EBITDA | -2.94 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 91.50% |
| Shares Outstanding | $147.37M |
| Float | $1.24B |
| % Insiders | 0.01% |
| % Institutions | 2.01% |